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Abstract. The detection of certain oncogenic driver mutations, 
including those of epidermal growth factor receptor (EGFR), 
is essential for determining treatment strategies for advanced 
non‑small cell lung cancer (NSCLC). The current study assessed 
the feasibility of testing exhaled breath condensate (EBC) for 
EGFR mutations by droplet digital PCR (ddPCR). Samples 
were collected from 12 patients with NSCLC harboring EGFR 
mutations that were admitted to Okayama University Hospital 
between June 1, 2014 and December 31, 2017. A total of 21 EBC 
samples were collected using the RTube™ method and EGFR 
mutations (L858R, exon 19 deletions or T790M) were assessed 
through ddPCR analysis (EBC‑ddPCR). A total of 3 healthy 
volunteer samples were also tested to determine a threshold 
value for each mutation. Various patient characteristics were 
determined, including sex (3 males and 9 females), age (range 
54‑81 years; median, 66 years), smoking history (10 had 
never smoked; 2 were former smokers), histology (12 patients 
exhibited adenocarcinoma), clinical stage (9 patients were 
stage IV; 3 exhibited post‑operative recurrence) and EGFR 
mutation type (4 had L858R; 8 had exon 19 deletions; 8 had 
T790M). EBC‑ddPCR demonstrated positive droplets in 8 of 
the 12 patients. The sensitivity and specificity of each muta‑
tion was as follows: 27.3 and 80.0% for EGFR L858R, 30.0 
and 90.9% for EGFR Ex19del, and 22.2 and 100% for EGFR 
T790M. EBC‑ddPCR analysis of EGFR mutations exhibited 
modest sensitivity and acceptable specificity. EBC‑ddPCR is 
a minimally invasive and replicable procedure and may be a 
complementary method for EGFR testing in patients where 
blood or tissue sampling proves difficult.
Introduction
The detection of oncogenic driver mutations, such as epidermal 
growth factor receptor (EGFR) mutations, is essential for deter‑
mining treatment strategies for advanced non‑small cell lung 
cancer (NSCLC). The EGFR‑tyrosine kinase inhibitor (TKI) is 
among the most successful treatments for NSCLC with EGFR 
mutations, as it extends the median overall survival by over 
30 months (1,2). A third‑generation EGFR‑TKI, osimertinib, 
has been clinically approved for lung cancers harboring the 
acquired resistance mutation EGFR T790M (3). However, the 
invasive tissue biopsy required for EGFR testing is often chal‑
lenging. Indeed, data show that re‑biopsy was not performed in 
20‑50% of patients treated with EGFR‑TKIs, raising questions 
on the viability of this method (4‑6).
Liquid biopsies that assess circulating tumor DNA from 
blood samples have been developed, providing an alternative 
for biomarker identification (7,8). Other samples, such as 
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exhaled breath condensate (EBC) and urine, have also been 
tested as alternatives to liquid biopsy (9‑12).
We previously reported the detection of EGFR exon 19 
deletion (Ex19del) mutations in EBC by conventional 
polymerase chain reaction (PCR) (13). Recently, a highly 
sensitive droplet digital PCR (ddPCR) was developed for 
liquid biopsy (14‑16). In this study, we investigated whether 
EBC testing using ddPCR (EBC‑ddPCR) for EGFR mutations 
is viable in patients with NSCLC.
Patients and methods
Clinical samples and lung cancer cell lines. Patients with lung 
cancer harboring the EGFR mutations L858R, Ex19del, or 
T790M were enrolled in this study between June 1, 2014 and 
December 31, 2017 after obtaining written informed consent. 
All patients were diagnosed with NSCLC using surgical 
tissue samples, biopsy specimens, or cytology samples. The 
diagnosis was based on the General Rules for the Clinical 
and Pathological Classification of Lung Cancer of the Japan 
Lung Cancer Society (8th edition) and TNM staging system 
of the International Association for the Study of Lung Cancer 
(8th edition) (17). Written informed consent was also obtained 
from three healthy volunteers. The baseline EGFR muta‑
tions of lung cancers were confirmed by clinically approved 
methods in Japan by practically examining surgical tissues, 
biopsy specimens, or cytology samples. Approximately 1‑2 ml 
of EBC was collected using RTube™ (Respiratory Research), 
according to the manufacturer's protocol. After collecting the 
EBC, 1‑ml aliquots were dispensed and stored at ‑80˚C. This 
study was approved by the Ethics Committee of Okayama 
University (Authorization number: 2221).
The lung cancer cell line H3255 harboring EGFR L858R 
was kindly provided by Dr William Pao (Vanderbilt University, 
Nashville, TN, USA) (18). The gefitinib‑resistant lung cancer 
cell lines RPC‑9 harboring EGFR Ex19del and T790M were 
previously established in our laboratory (19).
Droplet digital PCR assay for EGFR mutation detection. 
DNA was extracted using the QIAamp DNA Mini kit 
(Qiagen GmbH) according to the manufacturer's protocol. 
DNA qualification was performed with a NanoDrop spectrom‑
eter (Thermo Fisher Scientific, Inc.). The following primer and 
probe kits were purchased from Bio‑Rad): ddPCR Mutation 
assay: EGFR p.L858R c.2573T>G (#10049550); ddPCR 
EGFR Exon 19 Deletions Screening kit (#12002392) and 
ddPCR Mutation assay: EGFR p.T790M, Human (#10049550).
ddPCR was performed at Biobank (Okayama University 
Hospital, Okayama, Japan) using the QX200 Droplet Digital 
PCR system (Bio‑Rad) according to the manufacturer's 
protocol. The following conditions were used for ddPCR: 
i) An initial denaturation step at 95˚C for 10 min followed 
by: ii) 45 cycles at 94˚C for 30 sec; and iii) 45 cycles at ˚C 
for 1 min, with a 4) final enzyme deactivation step at 98˚C for 
10 min. The ramp rate for all steps was 2˚C/sec. PCR prod‑
ucts were then subjected to analysis with a QX‑200 Droplet 
reader and QuantaSoft analysis software (Bio‑Rad), with a 
EGFR Specific Multiplex DNA Reference Standard (#HD802, 
Horizon Discovery) used as a positive control. The accuracy of 
the ddPCR was confirmed using serially diluted DNA of lung 
cancer cell lines (Fig. S1A‑F). The patient samples and control 
samples including EBC samples from three healthy‑volunteers 
Table I. Patient characteristics.
Patient number Sex Age (years) Smoking Stageb Baseline EGFR mts Biopsy site
  1 F 60 Never rec L858R ‑a
  2 M 68 Former IVB Ex19del RL lobe
  3 F 81 Never IVB Ex19del Pleural fluid
  4 F 74 Never IVB Ex19del RU lobe
  5 F 66 Never rec Ex19del RU lobe
  6 F 58 Never IVB Ex19del Pleural fluid
  7 M 76 Never IVA L858R Pleura
  8 F 67 Never rec L858R Middle lobe
  9 F 70 Former IVB L858R Pleural fluid
10 M 56 Never IVB Ex19del RU lobe
11 F 56 Never IVB Ex19del LL lobe
12 F 54 Never IVB Ex19del RL lobe
aSurgical tissue was used for EGFR testing. bClinical stage was determined based on 8th edition of the International Lung Cancer Staging 
System. EGFR, epidermal growth factor receptor; F, female; M, male; rec, recurrence; Ex19del, EGFR exon 19 deletion; RL, right lower; RU, 
right upper; LL, left lower
Table II. Healthy volunteer characteristics.
Healthy volunteer Sex Age Smoking
1 M 41 Never
2 M 33 Never
3 M 37 Never
M, male.
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or elution buffer AE from the QIAamp DNA Mini kit (Qiagen) 
as negative controls were tested to determine the threshold 
(Fig. S2A‑D). No droplets were detected for EGFR L858R or 
EGFR T790M, whereas positive reactions were observed for 
EGFR Ex19del in the negative control samples. Therefore, 
the threshold for positive results for EGFR Ex19del were 
analyzed with the receiver operating characteristic (ROC) 
using patient samples (Fig. S3). As a result, the threshold 
for EGFR mutation‑positive was defined as follows: EGFR 
L858R (≥0.01 copies/µl), EGFR Ex19del (≥0.5 copies/µl), and 
EGFR T790M (≥0.01 copies/µl).
Statistical analysis. Statistical analysis was performed using 
STATA software version 15.1 (StataCorp). ROC analysis was 
performed to determine the optimal threshold for epidermal 
growth factor receptor exon 19 deletion. The 95% confidence 
interval (CI) was calculated by using the Clopper‑Pearson 
exact method for binomial proportions.
Results
Patient characteristics and EBC samples. Patient and healthy 
control characteristics are detailed in Tables I and II, respec‑
tively. The median patient age was 66 years (range, 54‑81), 
comprising 3 males and 9 females: 10/12 were never‑smokers 
and 9/12 were in stage IV of the disease. Four lung tumors 
harbored EGFR L858R, whereas 8 tumors showed the EGFR 
Ex19del mutation (Table I). In total, 21 samples were collected 
from the 12 patients. Of these 21 samples, 11 were from patients 
with lung cancers harboring EGFR L858R and 10 were from 
patients with lung cancers harboring EGFR Ex19del. The timing 
of EBC collection and treatment history are shown in Fig. 1.
Nine EBC samples were collected from two patients at 
the time of initiation of EGFR‑TKI (Table III). In contrast, 
12 EBC samples were collected from ten patients at the time 
of the second biopsy (Table IV). There were no adverse events 
due to EBC sampling.
EBC‑ddPCR for EGFR mutations in patients. The 21 EBC 
samples from 12 patients were analyzed by ddPCR using EGFR 
L858R, Ex19del. or T790M primer sets. In the four patients 
with lung cancer harboring EGFR L858R, 3 of 11 EBC samples 
(sample nos. 1‑1, 8‑4, and 9‑4) were positive for EGFR L858R 
(Fig. 2A and Tables II and IV). In the 8 patients with lung 
cancer harboring EGFR Ex19del, 3/10 EBC samples (sample 
nos. 2‑1, 4‑1, and 11‑1) were positive for EGFR Ex19del (Fig. 2B 
and Table IV). In the 8 patients with lung cancer harboring 
EGFR T790M, 2/9 EBC samples (sample nos. 5‑1 and 11‑1) 
were positive for EGFR T790M (Fig. 2C and Table IV). No 
association was detected between the detection of mutations 
and T‑factor/tumor localization in the lung or quality/quantity 
of DNA in the EBC samples (Tables III and IV).
Consequently, the sensitivity of the EBC test for EGFR 
mutations was as follows: 27.3% (95% CI, 6.0‑61.0%) for EGFR 
L858R, 30.0% (95% CI, 6.7‑65.2%) for EGFR Ex19del, and 
22.2% (95% CI, 2.8‑60.0%) for EGFR T790M. The specificity 
Figure 1. Flow diagram of the clinical course of 12 patients with lung cancer harboring EGFR mutations and the time of biopsy or exhaled breath condensate 
sampling. *Three consecutive samples were collected. #Four consecutive samples were collected. EGFR, epidermal growth factor receptor; TKI, tyrosine 
kinase inhibitor; Ex19del, EGFR exon 19 deletions; Anti‑PD‑1 ab, anti‑programmed cell death‑1 antibody; Anti‑PD‑L1 ab, anti‑programmed cell death 
ligand‑1 antibody.
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Figure 2. Detection of EGFR mutations by EBC‑ddPCRA. (A) ddPCR was performed using EGFR L858R primer sets. EGFR L858R was amplified in EBC 
samples 1‑1, 8‑4 and 9‑4. (B) ddPCR was performed using EGFR exon 19 deletion primer sets. EGFR exon 19 deletions were amplified in EBC samples 2‑1, 
4‑1 and 11‑1. (C) ddPCR was performed using EGFR T790M primer sets. EGFR T790M was amplified in EBC samples 5‑1 and 11‑1. The black bars indicate 
the positive threshold, which was 0 copies/µl for EGFR L858R and EGFR T790M, and 0.5 copies/µl for EGFR exon 19 deletion. EGFR, epidermal growth 
factor receptor; EBC, exhaled breath condensate; ddPCR, droplet digital PCR; Ex19del, EGFR exon 19 deletions.
Table III. EBC‑ddPCR.
    Localization   260/280 
Patient no. Baseline EGFR mts Biopsy site T‑factor of lung tumors Sample no. DNA (ng) ratio EBC‑ddPCR
8 L858R RL lobe 2b Peri 8‑1 279.5 1.46 (‑)
     8‑2 133.5 1.37 (‑)
     8‑3 503.0 1.73 (‑)
     8‑4 250.0 1.86 L858R
9 L858R Pleural fluid 4 Center 9‑1 138.0 1.66 (‑)
     9‑2 257.0 1.53 (‑)
     9‑3 253.5 2.06 (‑)
     9‑4 267 1.99 L858R
     9‑5 181.5 1.37 (‑)
EBC, exhaled breath concentrate; ddPCR, droplet digital PCR; EGFR, epidermal growth factor receptor; mts, mutations; T‑factor, T‑factor of 
TNM staging system version 8; RL, right lower.
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was as follows: 80.0% (95% CI, 44.4‑97.7%) for EGFR L858R, 
90.9% (95% CI, 58.7‑99.8%) for EGFR Ex19del, and 100% 
(95% CI, 73.5‑100%) for EGFR T790M (Table V).
Clinical course of highlighted cases with lung adenocarci‑
noma, whose EGFR mutations were detected by EBC‑ddPCR
Patient number 8. A non‑smoking 67‑year‑old woman was 
diagnosed with synchronous double primary lung cancer 
composed of adenocarcinoma harboring EGFR L858R in the 
right lower lobe of the lung, and adenocarcinoma harboring 
EGFR Ex19del in the right upper lobe of the lung. A right lower 
lobectomy (pathological stage T2bN0M0 cStage IIA) and right 
segment 3a partial resection (pathological stage T1aN0M0 
cStage IA1) were performed, with four subsequent courses of 
adjuvant chemotherapy with a combination of cisplatin and 
vinorelbine. However, at 12 months post‑surgery, a new lesion 
appeared in the middle lobe. Transbronchial biopsy of the 
lesion revealed an adenocarcinoma harboring EGFR L858R. 
The patient's Eastern Cooperative Group Performance Status 
was grade 1, and thus gefitinib was administered at 250 mg 
daily. EBC was collected 1 day prior starting gefitinib and 
at 2, 16 and 62 days after gefitinib initiation. Gefitinib was 
discontinued from days 41‑62 because of liver damage, but 
later re‑administered at a reduced dosage of 250 mg every 
2 days. EBC‑ddPCR detected EGFR L858R only in the fourth 
sampling (21 days after gefitinib cessation). The maximum 
therapeutic effect of gefitinib was a partial response (Response 
Evaluation Criteria in Solid Tumors version 1.1), with a 
progression‑free survival of 48 months (Fig. 3A and B).
Patient number 11. A non‑smoking 56‑year‑old woman 
was diagnosed with adenocarcinoma in the left lower lobe 
of the lung (clinical stage T3N1M1b cStage IVB, multiple 
brain metastases, bone metastases). The patient's Eastern 
Cooperative Group Performance Status was grade 1. EGFR 
Ex19del was detected in the biopsied tissue, after which erlo‑
tinib was administered. However, at 12 months after initiating 
erlotinib, the primary tumor increased. Two subsequent cycles 
of cytotoxic chemotherapy with cisplatin and pemetrexed 
were administered, but the tumor regrew following treatment. 
Re‑biopsy was performed on primary lung tumor and EBC 
was collected at the same time. In addition to the baseline 
EGFR Ex19del mutation, EGFR T790M was also detected 
in the biopsy sample. Similarly, EGFR Ex19del and T790M 
Table IV. EBC‑ddPCR.
Patient 2nd‑biopsy EGFR   Localization Sample  260/280
no. EGFR mutations test Biopsy site T‑factor of lung tumors no. DNA (ng) ratio EBC‑ddPCR
  1 L858R + T790M Clamp LL lobe Txa Peri 1‑1 214.5 1.37 L858R
  2 Ex19del Clamp RL lobe 4 Center 2‑1 268.5 2.33 Ex19del
      2‑2 234.0 1.88 (‑)
  3 Ex19del + T790M Clamp Pleural fluid 2a Peri 3‑1 272.0 192.0 (‑)
  4 Ex19del + T790M TaqMan Blood 2a Peri 4‑1 244.5 2.17 Ex19del
  5 Ex19del + T790M Clamp CSF Txb Peri 5‑1 277.0 1.64 T790M
  6 Ex19del + T790M Clamp Pleural fluid 1b Peri 6‑1 280.5 2.07 (‑)
  7 L858R Clamp Pleural fluid 2a Peri 7‑1 420.5 1.55 (‑)
10 Ex19del + T790M Clamp Pleural fluid 1b Peri 10‑1 123.5 10.48 (‑)
      10‑2 163.5 4.41 (‑)
11 Ex19del + T790M Clamp LL lobe 3 Peri 11‑1 152.0 4.01 Ex19del + T790M
12 Ex19del + T790M Clamp RU lobe 2a Peri 12‑1 323.0 1.66 (‑)
aPost‑surgery recurrence and multiple lung metastasis; bpost‑surgery recurrence and mediastinum lymphoid metastasis, with no lung nodule 
observed. EBC, exhaled breath concentrate; ddPCR, droplet digital PCR; EGFR, epidermal growth factor receptor; T‑factor, T‑factor of TNM 
staging system version 8; Clamp, the peptide nucleic acid‑locked nucleic acid PCR clamp; TaqMan, TaqMan assay; Ex19del, EGFR exon 19 
deletion; LL, left lower; peri, peripheral; RL, right lower; RU, right upper; CSF, cerebrospinal fluid.
Table V. Sensitivity, specificity and predictive values of exhaled breath concentrate‑droplet digital PCR.
Parameter L858R Ex19del  T790M
Sensitivity (95% CI) 27.3 (6.0‑61.0) 30.0 (6.7‑65.2) 22.2 (2.8‑60.0)
Specificity (95% CI) 80.0 (44.4‑97.5) 90.9 (58.7‑99.8) 100 (73.5‑100)
Positive predictive value (95% CI) 60.0 (14.7‑94.7) 75.0 (19.4‑99.4) 100 (15.8‑100)
Negative predictive value (95% CI) 50.0 (24.7‑75.3) 58.8 (32.9‑81.6) 63.2 (38.4‑83.7)
95% CIs were calculated using the Clopper‑Pearson exact method for binomial proportions. Ex19del, EGFR exon 19 deletion; CI, confidence interval.
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were detected by the EBC‑ddPCR method. Subsequently 
osimertinib was administered and continued over 6 months, 
which caused a partial response (Response Evaluation Criteria 
in Solid Tumors version 1.1) (Fig. 3C and D).
Discussion
This study demonstrated that using EBC‑ddPCR to detect 
EGFR mutations is feasible and shows a modest sensitivity 
(20‑30%) and acceptable sensitivity (80‑100%) in patients with 
lung cancers harboring EGFR mutations.
Up to 60% of lung adenocarcinomas treated with first‑ or 
second‑generation EGFR‑TKIs develop resistant EGFR T790M 
mutations (20,21). However, third‑generation EGFR‑TKIs were 
only administered in 23.7% of patients (22). A negative result 
for EGFR T790M in re‑biopsied samples should not prevent 
physicians from performing a repeat biopsy; however, it is 
not always possible to carry out repeat biopsies (21,23). The 
sensitivity of EBC testing for EGFR mutations was modest 
compared to that of blood tests (8); however, EBC testing is 
much more easily repeated because of its minimal invasive‑
ness. In this study, we performed three or four repeated EBC 
samplings without any adverse effects in both case 8 and 9. 
Although we did not assess the concordance between tissue 
biopsy and EBC testing on a larger scale, gefitinib and osimer‑
tinib inhibited the lung tumor in cases 8 and 11, respectively, 
with both the tissue biopsy and EBC testing detecting EGFR 
L858R or EGFR Ex19del and T790M. These cases suggest 
the potential of EBC testing as a complementary option for 
patients in whom tissue biopsy is difficult or for those who 
refuse repeated blood sampling.
Although ddPCR is thought to detect 0.005‑0.1% of 
target DNA (24), this study revealed a modest sensitivity 
for EGFR mutations in EBC samples (20‑30%). Smyth et al 
reported that EGFR T790M was detected in 9/10 EBC samples 
by UltraSEEK™ technology (12). Possible explanations for the 
discrepancy between the previous report and our study are differ‑
ences in sample quality and sensitivity of the detection methods.
This study had several limitations. The sample size was 
small (n=21 in 12 patients) and the number of EBC samples 
from treatment naïve patients and samples prior to initiating 
EGFR‑TKI were from only 1 case; therefore, patient bias should 
be considered. Furthermore, concordance among EBC testing, 
blood testing, and tissue biopsy was not assessed in detail. 
Therefore, these data should be considered as exploratory.
EBC‑ddPCR for EGFR mutations by ddPCR was feasible 
and showed moderate sensitivity and acceptable specificity. 
EBC sampling is minimally invasive and replicable; there‑
fore, EBC tests could be a complementary option for patients 
in whom tissue biopsy is difficult or for those who refuse 
repeated blood sampling. Further studies are needed to explore 
the potential of the EBC test.
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